Key result
Infection with HCV genotype 3, compared to genotype 2, was associated with younger age (p=0.002), less arterial hypertension (p=0.03), more advanced liver fibrosis (p=0.03), and steatosis (p=0.001).
Why the study?
Do clinical, epidemiological, laboratory, and histological differences exist between chronic hepatitis C genotypes 2 and 3?
Observational (n=306)
Do clinical, epidemiological, laboratory, and histological differences exist between chronic hepatitis C genotypes 2 and 3?
Clinical and histological differences exist between HCV-2 and HCV-3, including more advanced fibrosis and steatosis in HCV-3, suggesting they should be analyzed separately.
Answers are grounded in this paper and cite their sources.
HCV-3 findings should not yet change practice; leaves open whether genotypes 2 and 3 require distinct fibrosis management.
INTRODUCTION: Six genotypes of the hepatitis C virus (HCV) have been identified thus far, and their distribution is well defined. Genotype 1, which is the most prevalent worldwide, is always compared to genotypes 2 and 3, particularly in terms of treatment response. However, little is known about the differences between genotypes 2 and 3 because these genotypes are analyzed together in most studies. Therefore, the aim of this study was to evaluate differences in the clinical, epidemiological, laboratory, and histological parameters between HCV-2 and HCV-3. METHODS: Patients with chronic hepatitis C infected with genotypes 2 and 3 were studied retrospectively and compared according to clinical, laboratory, and histological aspects. Hepatitis C virus-ribonucleic acid (HCV-RNA) was analyzed quantitatively by TaqMan® real-time PCR, and the HCV genotype was determined by sequencing the 5'-untranslated region. RESULTS: A total of 306 patients with chronic HCV-2 (n=50) and HCV-3 (n = 256) were studied. Subtype 2b (n=17/50) and subtype 3a (n=244/256) were the most prevalent among patients infected with HCV-2 and HCV-3, respectively. The mean age was 47 ± 10 years, and there was a predominance of men in the group studied (61%). Comparative analysis between HCV-2 and HCV-3 showed a younger age (p=0.002), less prevalence of arterial hypertension (p=0.03), higher serum albumin levels (p=0.01), more advanced stage of liver fibrosis (p=0.03), and higher frequency of steatosis in patients with HCV-3 (p=0.001). After multivariate regression analysis, all the variables, except serum albumin, remained as variables associated with HCV-3 in the final model. CONCLUSIONS: Clinical and histological differences exist between HCV-2 and HVC-3, which suggests the need for separate analyses of these genotypes.
No takes yet. Share an insight, caveat, or question.
Melo et al. (2014) conducted an observational in Chronic hepatitis C (n=306). HCV genotype 3 vs. HCV genotype 2 was evaluated on Clinical, epidemiological, laboratory, and histological parameters. Infection with HCV genotype 3, compared to genotype 2, was associated with younger age (p=0.002), less arterial hypertension (p=0.03), more advanced liver fibrosis (p=0.03), and steatosis (p=0.001).
Synapse has enriched 10 related papers. Consider them for comparative context: